SCHEMBL13626998

SCHEMBL13626998

COc1cc(-c2cc(OC)cc(C(C)(C)C)c2OPOc2ccc3ccccc3c2)c(OPOc2ccc3ccccc3c2)c(C(C)(C)C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.47
CYP2A6 P11509 1/20 0.47
NQO2 P16083 1/20 0.39
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
RAB9A P51151 2/20 0.36
TNFRSF1A P19438 2/20 0.34
ALOX5 P09917 1/20 0.34
NPC1 O15118 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
CYP2B6 P20813 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13626999 0.85 BACE1 (0.39) CA1CA2LMNASMN1; SMN2TDP1
SCHEMBL13627009 0.85 CYP1A2 (0.38) CYP1A2CYP2A6CA1CA2LMNA
SCHEMBL14586979 0.84 CYP3A4 (0.41) HTTSMN1; SMN2L3MBTL1RAB9ANPC1
SCHEMBL13932560 0.77 CA2 (0.59) CA1CA2LMNASMN1; SMN2TNFRSF1A
SCHEMBL13627002 0.77 CYP2A6 (0.38) CYP1A2CYP2A6CA1CA2HTT
SCHEMBL19754872 0.75 CA1 (0.37) CA1CA2SMN1; SMN2CYP3A4CYP2C9
SCHEMBL18133831 0.73 CA1 (0.50) CYP1A2CYP2A6NQO2CA1CA2
SCHEMBL15062176 0.73 CA1 (0.36) CA1CA2TNFRSF1A
SCHEMBL16705219 0.72 CYP2A6 (0.58) CYP1A2CYP2A6CA1CA2TDP1
SCHEMBL14586980 0.71 CYP1A2 (0.35) CYP1A2LMNAL3MBTL1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615645-B2 Method for the continuous production of aldehydes BASF AKTIENGESELLSCHAFT (DE) 2009-11-10 US disclosed
US-20070083066-A1 Method for the production of 1,7-octadiene and use thereof BASF AKTIENGESELLSCHAFT (DE) 2007-04-12 US disclosed
US-20070004939-A1 Method for the continuous production of aldehydes VOLLAND MARTIN 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004939-A1 Method for the continuous production of aldehydes HRH4, HRH2, HRH3 CYP1A2 157/4885CYP2A6 207/4885NQO2 867/4885
US-20070083066-A1 Method for the production of 1,7-octadiene and use thereof CYP51A1, MSMO1, HSD17B7 CYP1A2 33/4885CYP2A6 57/4885NQO2 385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.